Helix and AstraZeneca Expand Collaboration in Genomics

Helix, the leading enterprise genomics company, announced a multi-year relationship with AstraZeneca, a global biopharmaceutical company. Under this agreement AstraZeneca will gain access to Helix's continuously growing, deeply phenotyped GenoSphere™ cohorts that cover a wide range of disease areas. 

"Our collaboration with AstraZeneca highlights how integrated large-scale clinico-genomic data is becoming a foundational resource in advancing biomedical research and therapeutic development," said James Lu, M.D., Ph.D., CEO and co-founder of Helix. "By combining comprehensive genomic data with rich longitudinal clinical information, we can help accelerate research, generate deeper insights into disease, and advance the development of more targeted medicines."